STORM Therapeutics will showcase research on its innovative METTL1 tRNA Methyltransferase blockers at the ESMO event for specialized cancer treatments.
Upadacitinib acts as an ATP-competitive JAK inhibitor; it competes with ATP and blocks nucleotide binding to inhibit kinase activity and the phosphorylation of downstream effectors.
Aleta Biotherapeutics and Cancer Research UK’s Centre for Drug Development has initiated dosing in the early-stage ALETA-001 clinical study, targeting individuals with recurrent or unresponsive B-cell cancers.
Dextromethorphan (DXM) is a synthetic analog of codeine, but unlike codeine, it is not a narcotic and does not have the same potential for abuse or addiction.
FDA has sanctioned a biweekly administration of TECVAYLI® (teclistamab-cqyv) as a therapeutic option for those suffering from recurring or unresponsive multiple myeloma.